Publication of clinical data confirming uPAR as an attractive target for guiding surgery in head and neck cancer
Copenhagen, Denmark, 22 August 2022. FluoGuide A/S ("FluoGuide" or the “Company”) is pleased to announce a publication of clinical data that shows uPAR is highly expressed in oropharyngeal squamous cell carcinoma.The article is published in ONCOLOGY REPORTS 48: 147, 2022: https://www.spandidos-publications.com/10.3892/or.2022.8359The article documents the relevance of uPAR as target for guiding surgery of head and neck cancers relative to other molecular targets and was recently published online in the journal “Oncology reports” with the title “Expression patterns of uPAR, TF and EGFR and